drugset / Trial / NCT01962935

Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069

NCT01962935

Phase 1 Completed 84 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindBasic science

Summary

Study to investigate safety, tolerability and effect of multiple dosing with AZD 4721 and/or with AZD 5069

Timeline

Start
2013-11
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator AZD5069 Small molecule
Subject VIMNERIXIN Small molecule